Prosecution Insights
Last updated: April 19, 2026

Examiner: CHANNAVAJJALA, LAKSHMI SARADA

Tech Center 1600 • Art Units: 1611

This examiner grants 43% of resolved cases

Performance Statistics

43.3%
Allow Rate
-16.7% vs TC avg
862
Total Applications
+2.1%
Interview Lift
1461
Avg Prosecution Days
Based on 856 resolved cases, 2023–2026

Rejection Statute Breakdown

1.0%
§101 Eligibility
10.7%
§102 Novelty
48.6%
§103 Obviousness
17.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17421747 LTA4H INHIBITORS FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA Final Rejection NOVARTIS AG
17418091 PHARMACEUTICAL PREPARATION Final Rejection KOWA COMPANY, LTD.
18098014 Optimized Topical Formulation for Lidocaine Pain Relief Gel Non-Final OA Focus Consumer Healthcare, LLC
17650594 NANOPARTICLE ISOFLAVONE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME Final Rejection Humanetics Corporation
17618020 MICRONIZED DRUG RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREPARATION THEREOF Final Rejection Brillian Pharma Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month